Evidence map›Paper›PMID 25515097›Full record

ArticleSleep2015

Central and peripheral metabolic changes induced by gamma-hydroxybutyrate.

Gianina Luca, Julie Vienne, Angélique Vaucher, Sonia Jimenez, Mehdi Tafti

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sleep, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Patient-Reported Measures of Narcolepsy: The Need for Better Assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Gianina LucaCenter for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland.
Julie VienneDepartment of Biology, Brandeis University, Waltham, MA.
Angélique VaucherCenter for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland.
Sonia JimenezCenter for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland.
Mehdi TaftiCenter for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland.
University of Lausanne · CHBrandeis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesGamma-hydroxybutyrate (GHB) was originally introduced as an anesthetic but was first abused by bodybuilders and then became a recreational or club drug.1 Sodium salt of GHB is currently used for the treatment of cataplexy in patients with narcolepsy. The mode of action and metabolism of GHB is not well understood. GHB stimulates growth hormone release in humans and induces weight loss in treated patients, suggesting an unexplored metabolic effect. In different experiments the effect of GHB administration on central (cerebral cortex) and peripheral (liver) biochemical processes involved in the metabolism of the drug, as well as the effects of the drug on metabolism, were evaluated in mice.

designC57BL/6J, gamma-aminobutyric acid B (GABAB) knockout and obese (ob/ob) mice were acutely or chronically treated with GHB at 300 mg/kg. MEASUREMENTS AND

resultsRespiratory ratio decreased under GHB treatment, independent of food intake, suggesting a shift in energy substrate from carbohydrates to lipids. GHB-treated C57BL/6J and GABAB null mice but not ob/ob mice gained less weight than matched controls. GHB dramatically increased the corticosterone level but did not affect growth hormone or prolactin. Metabolome profiling showed that an acute high dose of GHB did not increase the brain GABA level. In the brain and the liver, GHB was metabolized into succinic semialdehyde by hydroxyacid-oxoacid transhydrogenase. Chronic administration decreased glutamate, s-adenosylhomocysteine, and oxidized gluthathione, and increased omega-3 fatty acids.

conclusionsOur findings indicate large central and peripheral metabolic changes induced by GHB with important relevance to its therapeutic use.

Indexed as

Alcohol OxidoreductasesAnimalsBody CompositionCell RespirationCerebral CortexCorticosteroneFatty Acids, Omega-3gamma-Aminobutyric AcidGlutamic AcidGlutathione DisulfideGrowth HormoneHydroxybutyratesLiverMaleMiceMice, Inbred C57BL4-hydroxybutyric acidAlcohol OxidoreductasesCorticosteroneFatty Acids, Omega-3gamma-Aminobutyric AcidGlutamic AcidGlutathione DisulfideGrowth Hormonehydroxyacid-oxoacid transhydrogenaseHydroxybutyratesMitochondrial ProteinsProlactinS-Adenosylhomocysteinesuccinic semialdehydeantioxidantbrainGHBlivermetabolomics

Identifiers

PMID25515097
PMCPMC4288612
OpenAlexW2071635822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.